96 related articles for article (PubMed ID: 28840048)
1. Recurrence of Chronic Myeloid Leukemia during Pregnancy Subsequently Achieving Complete Medical Remission.
Mikhael S; Pascoe A; Prezzato J
Case Rep Oncol Med; 2017; 2017():5651064. PubMed ID: 28840048
[TBL] [Abstract][Full Text] [Related]
2. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
3. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
Dou X; Qin Y; Huang X; Jiang Q
Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
[TBL] [Abstract][Full Text] [Related]
4. Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia.
Kimura S
Stem Cell Investig; 2016; 3():36. PubMed ID: 27583255
[TBL] [Abstract][Full Text] [Related]
5. Successful Planned Pregnancy through Vitrified-Warmed Embryo Transfer in a Woman with Chronic Myeloid Leukemia: Case Report and Literature Review.
Furukawa Y; Takahashi T; Suganuma R; Ohara M; Ota K; Kyozuka H; Yamaguchi A; Soeda S; Watanabe T; Komiya H; Mizunuma H; Fujimori K
Mediterr J Hematol Infect Dis; 2020; 12(1):e2020005. PubMed ID: 31934315
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
7. Cessation of tyrosine kinase inhibitors in patients with chronic-phase chronic myelogenous leukemia following durable complete molecular response: a single center facing the dilemma.
Iliakis T; Papadopoulou V; Diamantopoulos PT; Panayiotidis P; Zervakis K; Giannakopoulou N; Tilimidos G; Angelopoulou M; Siakantaris MP; Pangalis G; Mantzourani M; Variami E; Viniou NA
Anticancer Res; 2013 Aug; 33(8):3509-14. PubMed ID: 23898127
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors.
Kong JH; Winton EF; Heffner LT; Gaddh M; Hill B; Neely J; Hatcher A; Joseph M; Arellano M; El-Rassi F; Kim A; Khoury JH; Kota VK
J Clin Med; 2020 May; 9(5):. PubMed ID: 32443762
[TBL] [Abstract][Full Text] [Related]
9. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
[TBL] [Abstract][Full Text] [Related]
10. [Fertility and disease outcomes in patients with chronic myeloid leukemia].
Dou XL; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):980-985. PubMed ID: 32023726
[No Abstract] [Full Text] [Related]
11. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
12. Treatment-free remission in chronic myeloid leukemia.
Molica M; Naqvi K; Cortes JE; Paul S; Kadia TM; Breccia M; Kantarjian H; Jabbour EJ
Clin Adv Hematol Oncol; 2019 Dec; 17(12):686-696. PubMed ID: 31851157
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia.
Tiribelli M; Eskazan AE
Oncol Ther; 2019 Dec; 7(2):95-100. PubMed ID: 32699984
[TBL] [Abstract][Full Text] [Related]
14. Successful Pregnancy and Delivery in a Patient with Chronic Myeloid Leukemia while on Dasatinib Therapy.
Conchon M; Sanabani SS; Serpa M; Novaes MM; Nardinelli L; Ferreira PB; Dorliac-Llacer PE; Bendit I
Adv Hematol; 2010; 2010():136252. PubMed ID: 20224653
[TBL] [Abstract][Full Text] [Related]
15. Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.
Huang X; Jiang Q; Hu J; Li J; Jin J; Meng F; Shen Z; Liu T; Wu D; Wang J; Wang J
Front Med; 2019 Jun; 13(3):344-353. PubMed ID: 30159669
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS).
Cirmi S; El Abd A; Letinier L; Navarra M; Salvo F
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235443
[TBL] [Abstract][Full Text] [Related]
17. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
[TBL] [Abstract][Full Text] [Related]
18. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Flynn KE; Myers JM; D'Souza A; Schiffer CA; Thompson JE; Atallah E
Oncologist; 2019 Sep; 24(9):1253-1258. PubMed ID: 30944185
[TBL] [Abstract][Full Text] [Related]
19. NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.
Shah NP
J Natl Compr Canc Netw; 2019 May; 17(5.5):611-613. PubMed ID: 31117031
[TBL] [Abstract][Full Text] [Related]
20. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
